Heparin Cardioversion Prophylaxis for AF >48 Hours or Unknown Duration
For patients with atrial fibrillation lasting >48 hours or of unknown duration requiring immediate/emergency cardioversion due to hemodynamic instability, administer intravenous unfractionated heparin (UFH) as a bolus followed by continuous infusion (targeting aPTT 1.5-2 times control), or weight-adjusted therapeutic-dose low-molecular-weight heparin (LMWH), immediately before cardioversion, then continue oral anticoagulation for at least 4 weeks post-cardioversion. 1, 2, 3, 4
Clinical Algorithm for Heparin Use
Emergency/Immediate Cardioversion (Hemodynamically Unstable)
When patients present with hemodynamic instability (angina, MI, shock, pulmonary edema):
- Start anticoagulation immediately - do not delay cardioversion 1, 2, 4
- UFH regimen: IV bolus followed by continuous infusion adjusted to aPTT 1.5-2× control 3
- LMWH alternative: Weight-adjusted therapeutic dose (e.g., enoxaparin 1 mg/kg subcutaneously twice daily) 1, 4
- Post-cardioversion: Continue oral anticoagulation (warfarin INR 2.0-3.0 or NOAC) for minimum 4 weeks 1, 2, 4
- Long-term: Base continuation beyond 4 weeks on thromboembolic risk (CHA₂DS₂-VASc score), not cardioversion success 4, 5
Elective Cardioversion (Hemodynamically Stable)
For planned cardioversion in stable patients, you have two evidence-based pathways:
Option 1: Conventional 3-Week Pre-Anticoagulation
- Oral anticoagulation (warfarin INR 2.0-3.0 or NOAC) for 3 weeks before cardioversion 1, 2, 4, 5
- Continue for minimum 4 weeks post-cardioversion 1, 2, 4
Option 2: TEE-Guided Approach with Abbreviated Anticoagulation
- Start therapeutic anticoagulation immediately (UFH or LMWH at full VTE treatment doses) 4
- Perform TEE to exclude left atrial/appendage thrombus 1, 2, 3
- If no thrombus: proceed with cardioversion while maintaining therapeutic anticoagulation 1, 3
- Continue anticoagulation minimum 4 weeks post-cardioversion 1, 4
- If thrombus present: continue oral anticoagulation for 3 weeks, repeat TEE, then cardiovert if resolved 1, 6
Specific Heparin Dosing
Unfractionated Heparin:
- Initial IV bolus (typically 60-80 units/kg, max 5000 units)
- Continuous infusion starting at 12-18 units/kg/hour
- Adjust to maintain aPTT 1.5-2× control value 3, 7, 3
Low-Molecular-Weight Heparin:
- Enoxaparin: 1 mg/kg (100 IU anti-Xa/kg) subcutaneously twice daily 8, 9, 10
- Dalteparin: 100 IU/kg subcutaneously twice daily 11
- No routine laboratory monitoring required 8, 11
- Continue until oral anticoagulation therapeutic (INR ≥2.0) 8, 10
Critical Nuances and Pitfalls
Atrial Stunning Risk: The highest thromboembolic risk occurs in the first 7-10 days post-cardioversion due to atrial mechanical stunning, even when pre-cardioversion TEE shows no thrombus 7, 12. This is why 4 weeks of post-cardioversion anticoagulation is mandatory regardless of pre-cardioversion strategy.
AF Duration <48 Hours: While guidelines are more permissive for shorter duration AF, recent evidence suggests thrombi can form within hours 11, 12. For patients with CHA₂DS₂-VASc ≥2 (men) or ≥3 (women), therapeutic anticoagulation with heparin or LMWH before cardioversion followed by long-term anticoagulation is reasonable 5. The 2019 AHA/ACC/HRS update strengthened this recommendation from Class I to Class IIa 5.
LMWH Advantages: Multiple studies demonstrate LMWH is safe and effective for peri-cardioversion anticoagulation 8, 9, 10. Benefits include: no IV access required, no aPTT monitoring, predictable pharmacokinetics, and potential for outpatient management 8, 11. The AFFECT trial showed only 1.5% major bleeding with fixed-dose certoparin 8000 U twice daily 8.
NOACs vs Heparin: While the 2018 CHEST guidelines and 2019 AHA/ACC/HRS update support NOACs as alternatives to warfarin for the 3-week pre-cardioversion period 4, 5, parenteral anticoagulation (UFH or LMWH) remains the standard for immediate/emergency cardioversion because of rapid onset of action 1, 2, 4.
Post-Cardioversion Duration: The mandatory 4-week post-cardioversion anticoagulation applies regardless of baseline stroke risk or apparent maintenance of sinus rhythm 1, 4, 5. Decisions about continuing anticoagulation beyond 4 weeks should be based on CHA₂DS₂-VASc score, not cardioversion success 4, 5.